Drugs & Targets FDA seeks academic and patient advocate research partners for oncology data analysis September 12, 2025Vol.51 No.33
Cancer Policy The departure (and return) of Vinay Prasad September 05, 2025Vol.51 No.32By Claire Marie Porter
Cancer Policy Trump administration wants to rebuild stockpile of APIs to address drug shortages September 05, 2025Vol.51 No.32By Sara Willa Ernst
Cancer Policy FDA will speed up public release of Complete Response Letters September 05, 2025Vol.51 No.32By Sara Willa Ernst
Drugs & Targets FDA approves expanded indication for Avtozma intravenous formulation in cytokine release syndrome September 05, 2025Vol.51 No.32
Drugs & Targets FDA grants breakthrough designation for Rina-S in advanced endometrial cancer September 05, 2025Vol.51 No.32
Podcast Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book August 27, 2025
Book ReviewFree When public service ends abruptly, do books provide solace? An escape? Perspective?Former NIH and FDA employees tell us what they are reading in 2025 August 08, 2025Vol.51 No.31By Sara Willa Ernst
Drugs & TargetsFree FDA gives accelerated approval to Modeyso as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma August 08, 2025Vol.51 No.31
News Analysis Vinay Prasad falls from grace at FDA upon flunking Trump political purity testMAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? August 01, 2025Vol.51 No.30By Claire Marie Porter
